"Apolipoprotein E4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.
| Descriptor ID |
D053327
|
| MeSH Number(s) |
D10.532.091.500.750 D12.776.070.400.500.750 D12.776.521.120.500.750
|
| Concept/Terms |
Apolipoprotein E4- Apolipoprotein E4
- Apolipoprotein E-4
- Apolipoprotein E 4
- Apo E4
- ApoE4
- Apo E epsilon 4
- Apo E-4
- Apo E 4
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein E4".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein E4".
This graph shows the total number of publications written about "Apolipoprotein E4" by people in this website by year, and whether "Apolipoprotein E4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein E4" by people in Profiles.
-
APOE4, Blood Neurodegenerative Biomarkers, and Cognitive Decline in Community-Dwelling Older Adults. JAMA Netw Open. 2025 May 01; 8(5):e258903.
-
Longitudinal associations between lipid panel and cognitive decline modified by APOE 4 carrier status in biracial community-dwelling older adults: Findings from the Chicago health and aging project. Arch Gerontol Geriatr. 2025 Jul; 134:105825.
-
Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD. Mol Neurodegener. 2025 02 04; 20(1):15.
-
Dietary fats and the APOE-e4 risk allele in relation to cognitive decline: a longitudinal investigation in a biracial population sample. J Nutr Health Aging. 2024 May; 28(5):100211.
-
Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer's dementia. Alzheimers Res Ther. 2022 10 11; 14(1):152.
-
Associations Between Cardiovascular Risk, Structural Brain Changes, and Cognitive Decline. J Am Coll Cardiol. 2020 05 26; 75(20):2525-2534.
-
Sex differences in Alzheimer's disease and common neuropathologies of aging. Acta Neuropathol. 2018 12; 136(6):887-900.
-
Cognitive Aging in Black and White Americans: Cognition, Cognitive Decline, and Incidence of Alzheimer Disease Dementia. Epidemiology. 2018 01; 29(1):151-159.
-
APOE e4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans. PLoS One. 2017; 12(7):e0180356.
-
Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology. J Alzheimers Dis. 2017; 56(2):699-706.